Equities research analysts expect that Express Scripts Holding (NASDAQ:ESRX) will post $24.76 billion in sales for the current fiscal quarter, Zacks reports. Eleven analysts have made estimates for Express Scripts’ earnings, with the highest sales estimate coming in at $25.50 billion and the lowest estimate coming in at $24.28 billion. Express Scripts posted sales of $24.65 billion during the same quarter last year, which would indicate a positive year-over-year growth rate of 0.4%. The company is expected to announce its next earnings results on Monday, April 23rd.
According to Zacks, analysts expect that Express Scripts will report full year sales of $24.76 billion for the current financial year, with estimates ranging from $99.93 billion to $103.77 billion. For the next year, analysts expect that the business will report sales of $103.39 billion per share, with estimates ranging from $99.59 billion to $108.10 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Express Scripts.
Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $2.16 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.09 by $0.07. The firm had revenue of $25.38 billion during the quarter, compared to analysts’ expectations of $25.07 billion. Express Scripts had a return on equity of 25.19% and a net margin of 4.51%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.88 EPS.
ESRX has been the subject of several recent research reports. Robert W. Baird raised Express Scripts from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $72.00 to $81.00 in a report on Friday, December 15th. Maxim Group cut Express Scripts from a “buy” rating to a “hold” rating in a research note on Thursday, March 8th. Zacks Investment Research cut Express Scripts from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Barclays initiated coverage on Express Scripts in a research note on Thursday, March 8th. They issued an “equal weight” rating and a $84.00 price target for the company. Finally, Jefferies Group set a $80.00 price target on Express Scripts and gave the company a “buy” rating in a research note on Friday, December 15th. Three analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have assigned a buy rating to the company. Express Scripts presently has an average rating of “Hold” and an average price target of $81.97.
In related news, VP Everett Neville sold 4,895 shares of the stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $75.26, for a total transaction of $368,397.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Glen D. Stettin sold 3,449 shares of the stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $81.00, for a total value of $279,369.00. Following the sale, the vice president now directly owns 33,715 shares of the company’s stock, valued at $2,730,915. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,792 shares of company stock valued at $909,815. 0.68% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ESRX. Swedbank acquired a new position in Express Scripts during the 4th quarter worth approximately $111,016,000. ValueAct Holdings L.P. acquired a new position in Express Scripts during the 4th quarter worth approximately $89,568,000. Two Sigma Advisers LP boosted its position in Express Scripts by 143.4% during the 4th quarter. Two Sigma Advisers LP now owns 1,782,736 shares of the company’s stock worth $133,063,000 after acquiring an additional 1,050,400 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Express Scripts by 23.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,233,327 shares of the company’s stock worth $331,374,000 after acquiring an additional 996,816 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in Express Scripts by 31.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 3,450,844 shares of the company’s stock worth $257,571,000 after acquiring an additional 835,464 shares during the last quarter. 89.08% of the stock is owned by institutional investors and hedge funds.
Shares of Express Scripts (NASDAQ:ESRX) traded down $0.31 during trading hours on Tuesday, reaching $76.02. The company’s stock had a trading volume of 5,503,470 shares, compared to its average volume of 5,322,636. The company has a market cap of $42,840.00, a PE ratio of 9.82, a P/E/G ratio of 0.94 and a beta of 0.94. Express Scripts has a 12-month low of $55.80 and a 12-month high of $85.07. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.67 and a quick ratio of 0.55.
Express Scripts announced that its board has initiated a share repurchase program on Monday, December 18th that allows the company to buyback 45,000,000 shares. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.
Express Scripts Company Profile
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.